Investors seeking the next obesity-like market opportunity will be closely watching developments related to treatments for ...

Groundbreaking research reveals potential link between cytomegalovirus (CMV) and Alzheimer's disease, offering new insights ...

The Florey Dementia Index (FDI) is valid for predicting the age of onset of mild cognitive impairment (MCI) and Alzhei ...

The Phase Ia trial is designed to assess the safety and efficacy of the company’s drug designed to target chemicals thought ...

New expensive but disease-modifying treatments are expected to foster Alzheimer’s disease market growth globally, according to a report. The report by GlobalData, a data and analytics company, showed ...

The Tennessee Lady Volunteers are set to host its annual “We Back Pat” game at Food City Center on Thursday against ...

Topline results from a phase 2b/3 clinical trial of blarcamesine for individuals with early-stage Alzheimer’s disease showed ...

BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today announced that the U.S. Food and Drug Administration (FDA) has accepted BioArctic's partner Eisai's Biologics License Application (BLA) for Leqembi ...

“There are things that we can do at all stages of our lives deliberately,” says Prof Schott. “It’s never too early to start ...

IGC Pharma, Inc (NYSE American:IGC) (”IGC” or the “Company”), today announced that CEO Ram Mukunda and CCO Claudia Grimaldi ...

Gum disease appears to disrupt brain activity, potentially increasing a person's risk of cognitive decline. People with gum ...